Synergy Pharma (SGYP) Posts Q2 Loss of $0.23/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. SPY
8. UNH
9. SBUX
10. AXP

Go back to Synergy Pharma (SGYP) Posts Q2 Loss of $0.23/Share

Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update

August 8, 2016 5:00 PM EDT

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended June 30, 2016.

Our exciting transformation from a purely research and development company into a fully integrated commercial organization continues unabated as we successfully advance and execute against our key strategic priorities, said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals Inc. These priorities are guided by our overarching mission to optimize the value of plecanatide and maximize... More